Related Experiment Video
Updated: Jan 20, 2026
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
The Unique Role of Fluorodeoxyglucose-PET in Radioembolization
Remco Bastiaannet1, Martin A Lodge2, Hugo W A M de Jong3
1Department of Radiology and Nuclear Medicine, University Medical Center, Huispost E01.132, Postbus 85500, Utrecht 3508 GA, Netherlands; The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 N. Caroline St., Baltimore, MD 21287, USA.
Abstract:
Recent research into the efficacy of radioembolization has brought this field to an interesting position, in which fluorodeoxyglucose (FDG)-PET/CT is being used extensively for prognosis and response assessment, as well as a tool to define viable tumor volumes for the use in dosimetry. As such, there is an overlap with existing techniques used in radiotherapy; however, many are very specific to the radioembolization paradigm. This article describes the current state-of-the-art of the use of FDG-PET/CT for patient selection, prognosis, treatment evaluation, and as a research tool into absorbed dose-response relationships in radioembolization.
Related Concept Videos
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
01:18Other Unique Bacteria
01:16Second Uniqueness Theorem
In contrast, consider that the electric field is non-unique and apply Gauss's law in divergence form in the region between the conductors and the integral form to the surface...
05:27FDG Based PET/CT Scan: A Method of Using Radiotracer for Non-invasive Imaging of Tumor Metabolism
07:47Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma
10:46MRI and PET in Mouse Models of Myocardial Infarction